📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
0 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
239
GILD Latest News & AI Sentiment Analysis
0 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 5 ARTICLES
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
The article explores a potential strategic partnership between Merck and Gilead Sciences, two established biopharma leaders with...
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
MacroGenics (MGNX) received a $10 million milestone payment from Gilead Sciences (GILD) following Gilead's exercise of an option to...
Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings (NASDAQ:GILD)
Gilead Sciences (GILD) received a cautious upgrade following Q2 2026 results that delivered stronger operational performance than...
California Supreme Court Rules for Gilead, Says Drugmakers Don’t Have ‘Duty to Innovate’
California's Supreme Court decision establishes a significant legal precedent limiting litigation exposure for pharmaceutical...
Gilead Stock: Buy The Distortion Before Q2 Clears It Up (NASDAQ:GILD)
Gilead Sciences presents a favorable risk-reward positioning ahead of Q2 earnings clarification, with its HIV franchise demonstrating...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice